ATE532865T1 - Klammerartiges oligonukleotid und dieses enthaltender arzneistoff - Google Patents

Klammerartiges oligonukleotid und dieses enthaltender arzneistoff

Info

Publication number
ATE532865T1
ATE532865T1 AT04788459T AT04788459T ATE532865T1 AT E532865 T1 ATE532865 T1 AT E532865T1 AT 04788459 T AT04788459 T AT 04788459T AT 04788459 T AT04788459 T AT 04788459T AT E532865 T1 ATE532865 T1 AT E532865T1
Authority
AT
Austria
Prior art keywords
provides
oligonucleotides
specifically
dermatitis
diseases
Prior art date
Application number
AT04788459T
Other languages
English (en)
Inventor
Yasuo Kunugiza
Naruya Tomita
Hideo Hashimoto
Hideki Yoshikawa
Ryuichi Morishita
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE532865T1 publication Critical patent/ATE532865T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT04788459T 2003-09-30 2004-09-29 Klammerartiges oligonukleotid und dieses enthaltender arzneistoff ATE532865T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003341419 2003-09-30
PCT/JP2004/014694 WO2005030960A1 (ja) 2003-09-30 2004-09-29 ステイプル型オリゴヌクレオチドおよびそれからなる医薬

Publications (1)

Publication Number Publication Date
ATE532865T1 true ATE532865T1 (de) 2011-11-15

Family

ID=34386222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04788459T ATE532865T1 (de) 2003-09-30 2004-09-29 Klammerartiges oligonukleotid und dieses enthaltender arzneistoff

Country Status (8)

Country Link
US (1) US7595301B2 (de)
EP (1) EP1669450B1 (de)
JP (1) JPWO2005030960A1 (de)
CN (1) CN1860228B (de)
AT (1) ATE532865T1 (de)
AU (1) AU2004276684A1 (de)
CA (1) CA2538215A1 (de)
WO (1) WO2005030960A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
US20080311552A1 (en) * 2005-09-20 2008-12-18 London Health Sciences Centre Research, Inc. Use of Sirnas in Organ Storage/Reperfusion Solutions
JP5601777B2 (ja) * 2008-02-13 2014-10-08 株式会社ジーンデザイン 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ
GB2459922A (en) * 2008-05-13 2009-11-18 Univ Dundee Treatment for keratinizing dermatological disorders by reduction in keratin expression
EP2415869A4 (de) * 2009-04-03 2013-06-19 Biomics Biotechnologies Co Ltd Modifiziertes oligonukleotidsäuremolekül, herstellungsverfahren und verwendung
WO2011130371A1 (en) 2010-04-13 2011-10-20 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
TWI573870B (zh) * 2010-07-08 2017-03-11 Bonac Corp Single-stranded nucleic acid molecules used to control gene expression (I)
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
EP2674494B1 (de) * 2010-08-03 2014-12-17 Bonac Corporation Einzelsträngiges RNS-Molekül mit stickstoffhaltigem alizyklischen Gerüst
US9528111B2 (en) 2012-01-07 2016-12-27 Bonac Corporation Single-stranded nucleic acid molecule having amino acid backbone
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
WO2014170441A1 (en) * 2013-04-19 2014-10-23 Dna Therapeutics Inhibition of dna damage repair by artificial activation of parp with oligonucleotide molecules
JP6486836B2 (ja) 2013-12-26 2019-03-20 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
CN112646812A (zh) 2013-12-27 2021-04-13 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
US11027023B2 (en) 2014-12-27 2021-06-08 Bonac Corporation Natural type miRNA for controlling gene expression, and use of same
WO2016158809A1 (ja) 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
CN113004362B (zh) * 2021-02-26 2023-08-15 南方科技大学 一种订书钉核酸、dna纳米机器人及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
KR20000065690A (ko) * 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법

Also Published As

Publication number Publication date
AU2004276684A1 (en) 2005-04-07
US20060276421A1 (en) 2006-12-07
WO2005030960A1 (ja) 2005-04-07
EP1669450B1 (de) 2011-11-09
CN1860228A (zh) 2006-11-08
EP1669450A1 (de) 2006-06-14
EP1669450A4 (de) 2009-06-03
US7595301B2 (en) 2009-09-29
CN1860228B (zh) 2010-04-28
JPWO2005030960A1 (ja) 2006-12-07
CA2538215A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
ATE532865T1 (de) Klammerartiges oligonukleotid und dieses enthaltender arzneistoff
Hélène et al. Oligodeoxynucleotides covalently linked to intercalating agents: a new class of gene regulatory substances
Oyelere et al. p K a perturbation in genomic hepatitis delta virus ribozyme catalysis evidenced by nucleotide analogue interference mapping
Furukawa et al. Identification of ligand analogues that control c-di-GMP riboswitches
JP2005508947A5 (de)
NO20031192L (no) Isoksazoler og deres anvendelse som inhibitorer av ERK
WO2002097114A3 (en) Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
DE60329416D1 (de) Allelspezifische rna-interferenz
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
RU2004107852A (ru) Ингибирование stat-1
WO2006051552A3 (en) Directed evolution and selection using in vitro compartmentalization
EP2261334A3 (de) Modifizierte Polynukleotide zur Verwendung in RNA-Interferenz
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
Abbas et al. Glyceryl trinitrate is a novel inhibitor of quorum sensing in Pseudomonas aeruginosa
MXPA05011221A (es) Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi.
HK1090950A1 (en) Treatment of iga1 deposition diseases
Peselis et al. Cooperativity, allostery and synergism in ligand binding to riboswitches
JP2018531046A5 (de)
Yamamoto et al. Superior Silencing by 2′, 4′‐BNANC‐Based Short Antisense Oligonucleotides Compared to 2′, 4′‐BNA/LNA‐Based Apolipoprotein B Antisense Inhibitors
DE60333365D1 (de) Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
MX2007005069A (es) Composiciones y metodos para la inhibicion del acido nucleico corto de interferencia de nav1.8.
WO2005042719A3 (en) Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents
EP1697498A4 (de) Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese